secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-037176
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M
--------------------------------------------------------------------------------

- Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).
- Purchase price for Apexigen: $10.7M, comprising 4.3M Pyxis shares at $2.295/share.
- Intangible assets acquired: $24.5M (IPR&D $21.0M, royalty rights $3.5M).
- Nonrecurring transaction costs included: $1.7M in Pyxis G&A, $5.5M in Apexigen G&A.
- Severance costs of $4.7M recorded: $1.6M G&A, $3.1M R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024037176/0000950170-24-037176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024037176/pyxs-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer